Predict your next investment

Asset/Investment Management

See what CB Insights has to offer

Investments

49

Portfolio Exits

18

Funds

1

About Baker Brothers Investments

Baker Brothers Advisors is a financial organization, but much else isn't disclosed publicly about this company.

Baker Brothers Investments Headquarter Location

6667 Madison Ave Floor 17

New York, New York, 10021,

United States

212-339-5600

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Baker Brothers Investments News

Aquinox Announces Appointment of Dr. Kelvin Neu and Dr. Richard Levy to Board of Directors

Mar 27, 2017

Aquinox Announces Appointment of Dr. Kelvin Neu and Dr. Richard Levy to Board of Directors March 27, 2017 16:05 ET | Source: Aquinox Pharmaceuticals, Inc. VANCOUVER, British Columbia, March 27, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“ Aquinox ”) (NASDAQ: AQXP ), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced that representatives from Aquinox’s largest shareholder, Baker Brothers Investments, have been appointed to the Aquinox’s board of directors. Drs. and Richard S. Levy, M.D., joined effective March 23, 2017. Founded in 2000, Baker Brothers Investments manages long-term investment funds, focused on publicly traded life sciences companies, for major university endowments and foundations. “I would like to welcome Kelvin and Richard to the board. Baker Brothers Investments has been a strong supporter of the company and we have a shared vision for the potential of Aquinox. We will benefit immensely from an even closer working relationship, their deep insights on successful clinical development and experience working with many companies to bring novel therapies to market,” said David Main, President and CEO of Aquinox. “The strength of our board reflects our focus on late stage development and preparation for commercialization in support of the company’s goal to meaningfully improve the quality of patients’ lives through innovative medicines.” Kelvin M. Neu, M.D., is a Managing Director of Baker Brothers Investments. Dr. Neu holds an M.D. from the Harvard Medical School-MIT Health Sciences and Technology program, and spent three years in the Immunology Ph.D. program at Stanford University as a Howard Hughes Medical Institute Fellow. Richard S. Levy, M.D., is a Senior Advisor at Baker Brothers Investments. Dr. Levy, previously Executive Vice President, Chief Drug Development and Medical Officer at Incyte Corporation, is Board Certified in Internal Medicine and Gastroenterology and received his M.D. from the University of Pennsylvania School of Medicine. About Aquinox Pharmaceuticals, Inc. Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. In September 2016, we began enrolling patients in a Phase 3 clinical trial of AQX-1125 in our lead indication, Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Other indications are under consideration for future investigation. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com . Investor Contact Info:

Baker Brothers Investments Investments

49 Investments

Baker Brothers Investments has made 49 investments. Their latest investment was in Presidio Pharmaceuticals as part of their Series D on June 6, 2014.

CBI Logo

Baker Brothers Investments Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/16/2014

Series D

Presidio Pharmaceuticals

$21.83M

No

2

4/1/2013

Series C

Aquinox Pharmaceuticals

$18M

No

2

8/5/2011

Debt

Presidio Pharmaceuticals

$3M

No

3/21/2011

Series G

Subscribe to see more

$99M

Subscribe to see more

10

6/17/2010

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/16/2014

4/1/2013

8/5/2011

3/21/2011

6/17/2010

Round

Series D

Series C

Debt

Series G

Series B

Company

Presidio Pharmaceuticals

Aquinox Pharmaceuticals

Presidio Pharmaceuticals

Subscribe to see more

Subscribe to see more

Amount

$21.83M

$18M

$3M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

10

10

Baker Brothers Investments Portfolio Exits

18 Portfolio Exits

Baker Brothers Investments has 18 portfolio exits. Their latest portfolio exit was Presidio Bank on October 14, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/14/2019

Acq - P2P

4

8/2/2017

Merger

1

6/23/2014

Acq - P2P

$991

2

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

10/14/2019

8/2/2017

6/23/2014

00/00/0000

00/00/0000

Exit

Acq - P2P

Merger

Acq - P2P

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

1

2

10

10

Baker Brothers Investments Fund History

1 Fund History

Baker Brothers Investments has 1 fund, including Baker Brothers Life Sciences LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/27/2008

Baker Brothers Life Sciences LP

Multi-Stage Venture Capital

$155M

1

Closing Date

10/27/2008

Fund

Baker Brothers Life Sciences LP

Fund Type

Multi-Stage Venture Capital

Status

Amount

$155M

Sources

1

Baker Brothers Investments Team

2 Team Members

Baker Brothers Investments has 2 team members, including current Chief Financial Officer, Leo Kirby.

Name

Work History

Title

Status

Leo Kirby

Chief Financial Officer

Current

Julian C Baker

Founding Partner

Current

Name

Leo Kirby

Julian C Baker

Work History

Title

Chief Financial Officer

Founding Partner

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.